Supernus, Inc. SUPN
At closeNov 5, 2026, 4:53 PM EST
After hours · Nov 5, 4:53 PM ET
- YTD
- -25.47%
- 1 year
- -16.57%
- Market cap
- 1.56B
- Revenue (ttm)
- 1.37B
- Profit margin
- 32.75%
- EPS (ttm)
- -0.72
- Shares out
- 58.24M
- Forward P/E
- 6.76
- YTD return
- -25.47%
- 1-year return
- -16.57%
- Volume
- 6.08M
- Avg volume
- 2.49M
- Open
- 28.29
- Previous close
- 28.21
- Day's range
- 26.52 – 28.79
- 52-week range
- 26.52 – 42.81
- Beta
- 1.13
- Analysts
- Strong Buy
- Price target
- 49.50 (+85.1%)
- Earnings date
- Feb 25, 2027
5D -14.19 (-34.67%)
Key statistics
- Enterprise value
- 3.52B
- PEG ratio
- 0.00
- Price / sales
- 1.20
- Price / book
- 1.55
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 13.40%
- Free cash flow
- 227.12M
- Total cash
- 305.00M
- Total debt
- 501.00M
- Return on equity
- 0.00%
- Short % of float
- 8.51%
- 50-day average
- 42.42
- 200-day average
- 47.25
Analyst view
Consensus: strong buy
- Target (low)
- 45.00
- Target (mean)
- 49.50
- Target (high)
- 53.00
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate 1.22.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | 1.03 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 1.06 | 1.32 | +0.26 | +24.53% |
| Aug 3, 2026 | Jun 30, 2026 | 0.869 | 1.15 | +0.28 | +32.34% |
| Apr 30, 2026 | Mar 31, 2026 | 0.64 | 0.96 | +0.32 | +50.00% |
| Feb 26, 2026 | Dec 31, 2025 | 0.65 | 0.82 | +0.17 | +26.15% |
| Oct 30, 2025 | Sep 30, 2025 | 0.38 | 0.72 | +0.34 | +89.47% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 9, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Dec 19, 2025 | Stifel | main | Hold | Hold |
| Oct 29, 2025 | B of A Securities | init | — | Buy |
| Oct 23, 2025 | TD Cowen | main | Buy | Buy |
| Oct 9, 2025 | Piper Sandler | up | Neutral | Overweight |
| Sep 30, 2025 | Cantor Fitzgerald | main | Overweight | Overweight |
About Supernus, Inc.
Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Supernus, Inc. was formerly known as Indivior Pharmaceuticals, Inc. and changed its name Supernus, Inc. in November 2026. Supernus, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
News
Piper Sandler Reinstates Overweight on Supernus, Announces $47 Price Target 
Buy, Sell, or Hold? Wednesday’s Top Upgrades and Downgrades: Adobe, Apple, Duolingo, Exxon Mobil, Fiserv, Fortinet, Gartner, Lockheed Martin, Skyworks Solutions, Visa and More 
Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Wednesday 
Cantor Fitzgerald Maintains Overweight on Supernus, Raises Price Target to $87 
12 Health Care Stocks Moving In Tuesday's Intraday Session 
Why Indivior Pharmaceuticals Stock Topped the Market Today 
Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader 
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call Transcript 
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates 
Supernus Pharmaceuticals Q3 Earnings Call Highlights
Your note
Sign in to keep a note on SUPN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BlackRock, Inc. | — | Holding | Jun 26, 2025 | 8,269,109 |
| Crossley (Mark) | — | Bought | Mar 16, 2025 | 350,927 |
| Deerfield Partners LLC | — | Annual Return | Feb 27, 2025 | 6,567,399 |
| Kairos Capital Management, LLC | — | Annual Return | Feb 27, 2025 | 12,457,514 |
| Kalia (Vishal) | — | Bought | Mar 2, 2025 | 139,836 |
| Madison Avenue Partners LP | — | Increase | Mar 10, 2025 | 6,464,040 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 15.85% | 18,709,432 | 527.79M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 6.42% | 7,572,287 | 213.61M | Jun 29, 2026 |
| Oaktree Capital Management LP | 5.19% | 6,127,212 | 172.85M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.66% | 5,495,486 | 155.03M | Jun 29, 2026 |
| State Street Corporation | 4.23% | 4,992,071 | 140.83M | Jun 29, 2026 |
| Fuller & Thaler Asset Management Inc. | 3.91% | 4,615,816 | 130.21M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.95% | 7,028,347 | 198.27M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.28% | 3,873,712 | 109.28M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.62% | 3,097,715 | 87.39M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.37% | 2,797,172 | 78.91M | Jun 29, 2026 |
| Capitol Series Trust-FullerThaler Behavioral Small-Cap Growth Fund | 1.82% | 2,152,304 | 60.72M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.36% | 1,609,803 | 45.41M | Jun 29, 2026 |